表紙
市場調査レポート

ラクオリア創薬 : 製品パイプライン分析

RaQualia Pharma Inc. - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 203738
出版日 ページ情報 英文 43 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
ラクオリア創薬 : 製品パイプライン分析 RaQualia Pharma Inc. - Product Pipeline Review - 2016
出版日: 2016年07月30日 ページ情報: 英文 43 Pages
概要

ラクオリア創薬 は東京に拠点を置く、臨床および前臨床候補の薬剤を創薬・開発・商品化し、世界的に展開している製薬会社です。製品には胃不全麻痺、慢性便秘、神経因性疼痛、癌に伴う食欲不振、慢性炎症性疼痛、急性痛、アレルギー、アルツハイマー病などの治療薬があります。

当レポートでは、ラクオリア創薬における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを提供しています。

ラクオリア創薬の基本情報

ラクオリア創薬の概要

  • 主要情報
  • 企業情報

ラクオリア創薬:R&Dの概要

  • 主な治療範囲

ラクオリア創薬:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • アウトライセンス製品
    • アウトライセンス製品/併用療法モダリティ

ラクオリア創薬:パイプライン製品の概況

  • 最終段階にあるパイプライン製品
    • 第?相にある製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

ラクオリア創薬:薬剤プロファイル

  • RQ-00000004
  • RQ-00000010
  • RQ-00000774
  • RQ-00201894
  • RQ-00202730
  • RQ-00203066
  • RQ-00310941
  • RQ-00432933
  • 神経因性疼痛向け Cav3.2 阻害薬
  • 疼痛向け Nav1.7 ナトリウム・チャネル阻害薬
  • 疼痛向け Nav1.8 ナトリウム・チャネル阻害薬
  • 神経因性疼痛向け TRPM8 阻害薬
  • 未公表の症状向け特殊イオン・チャネル調整薬
  • 疼痛向け特殊イオン・チャネル調整薬

ラクオリア創薬:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

ラクオリア創薬:最近のパイプライン動向

ラクオリア創薬:休止中のプロジェクト

ラクオリア創薬:本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC08109CDB

Summary

Global Markets Direct's, 'RaQualia Pharma Inc. - Product Pipeline Review - 2016', provides an overview of the RaQualia Pharma Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by RaQualia Pharma Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of RaQualia Pharma Inc.
  • The report provides overview of RaQualia Pharma Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses RaQualia Pharma Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features RaQualia Pharma Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate RaQualia Pharma Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for RaQualia Pharma Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding RaQualia Pharma Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • RaQualia Pharma Inc. Snapshot
    • RaQualia Pharma Inc. Overview
    • Key Information
    • Key Facts
  • RaQualia Pharma Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • RaQualia Pharma Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • RaQualia Pharma Inc. - Pipeline Products Glance
    • RaQualia Pharma Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • RaQualia Pharma Inc. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • RaQualia Pharma Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • RaQualia Pharma Inc. - Drug Profiles
    • tegoprazan
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RQ-00000010
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RQ-00310941
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RQ-00000774
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RQ-00201894
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RQ-00202730
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RQ-00203066
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RQ-00203078
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RQ-00433412
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Block Cav3.2 for Neuropathic Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Block Nav1.7 Sodium Channel for Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Block Nav1.8 Sodium Channel for Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RQ-00434739
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Undisclosed Indication
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • RaQualia Pharma Inc. - Pipeline Analysis
    • RaQualia Pharma Inc. - Pipeline Products by Target
    • RaQualia Pharma Inc. - Pipeline Products by Route of Administration
    • RaQualia Pharma Inc. - Pipeline Products by Molecule Type
    • RaQualia Pharma Inc. - Pipeline Products by Mechanism of Action
  • RaQualia Pharma Inc. - Recent Pipeline Updates
  • RaQualia Pharma Inc. - Dormant Projects
  • RaQualia Pharma Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • RaQualia Pharma Inc., Key Information
  • RaQualia Pharma Inc., Key Facts
  • RaQualia Pharma Inc. - Pipeline by Indication, 2016
  • RaQualia Pharma Inc. - Pipeline by Stage of Development, 2016
  • RaQualia Pharma Inc. - Monotherapy Products in Pipeline, 2016
  • RaQualia Pharma Inc. - Phase III, 2016
  • RaQualia Pharma Inc. - Phase I, 2016
  • RaQualia Pharma Inc. - Preclinical, 2016
  • RaQualia Pharma Inc. - Discovery, 2016
  • RaQualia Pharma Inc. - Pipeline by Target, 2016
  • RaQualia Pharma Inc. - Pipeline by Route of Administration, 2016
  • RaQualia Pharma Inc. - Pipeline by Molecule Type, 2016
  • RaQualia Pharma Inc. - Pipeline Products by Mechanism of Action, 2016
  • RaQualia Pharma Inc. - Recent Pipeline Updates, 2016
  • RaQualia Pharma Inc. - Dormant Developmental Projects,2016
  • RaQualia Pharma Inc., Other Locations
  • RaQualia Pharma Inc., Subsidiaries

List of Figures

  • RaQualia Pharma Inc. - Pipeline by Top 10 Indication, 2016
  • RaQualia Pharma Inc. - Pipeline by Stage of Development, 2016
  • RaQualia Pharma Inc. - Monotherapy Products in Pipeline, 2016
  • RaQualia Pharma Inc. - Pipeline by Top 10 Target, 2016
  • RaQualia Pharma Inc. - Pipeline by Route of Administration, 2016
  • RaQualia Pharma Inc. - Pipeline by Molecule Type, 2016
  • RaQualia Pharma Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top